#10 Antioxidant Vitamin Cure-Alls: Will Good Theories Ever Die?
CLINICAL QUESTION
Does daily supplementation of antioxidant vitamins (A, E, and C) decrease mortality in the general population?
BOTTOM LINE
The current evidence does not support the use of antioxidant supplementation, and patients should be dissuaded from using beta-carotene, vitamin E, and perhaps high-dose vitamin A, as they appear to increase mortality by about 1 in every 250 over ~5 years.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
One Cochrane review1 of 78 Randomized Controlled Trials (RCTs) with 296,707 patients (~75% healthy participants, ~25% pre-existing condition):
- Focusing on high-quality RCTs:
- Antioxidants increased mortality with a Relative Risk (RR) of 1.04 (1.01-1.07), Number Needed to Harm (NNH)=238.
- Specifically:
- Beta-carotene (pro-vitamin A): RR 1.05 (1.01-1.09).
- Vitamin E: RR 1.03 (1.00-1.05).
- No statistically significant difference in mortality for:
- Vitamin A, all doses: RR 1.07 (0.97-1.18).
- High-dose vitamin A appears to increase mortality (p=0.002).
- High-dose not clearly defined, but appears to be >5000 IU.
- Vitamin C: RR 1.02 (0.98-1.07).
- Selenium: RR 0.97 (0.91-1.03).
- Vitamin A, all doses: RR 1.07 (0.97-1.18).
- If baseline mortality risk were around 10% over 3.5 years, about one in every 100 to 250 people taking antioxidants would die because of the supplements.
- Other meta-analyses report similar results. Examples:
- Antioxidant vitamins do not reduce the incidence of cardiovascular disease or cancer when taken for primary prevention.2
- Beta-carotene: Statistically significant increased mortality (NNH=167-326).2-4
- Vitamin E:
- No difference in mortality in 101,343 healthy individuals: RR 1.01 (0.98-1.04).2
- High-dose (>400 IU): Statistically significant increased mortality (NNH=257).5,6
- While theories and previous observational studies suggested potential benefit with antioxidant vitamins, this has been disproven by higher-level evidence.
- Theories of disease and treatment/prevention are common in medicine. We must guard against the superficial appeal of these theories and rely on evidence of benefit or harm to guide the care of our patients.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
